In the claims:

1-40. **(Canceled)**

41. **(New)** An isolated polynucleotide encoding a polypeptide that is at least 70% similar to SEQ ID NO:2.

42. **(New)** An isolated polynucleotide encoding a mature polypeptide that is at least 70% similar to the mature polypeptide part of SEQ ID NO:2.

43. **(New)** The polynucleotide of claim 41 or 42 which is at least 90, preferably 95% similar to SEQ ID NO:2.

44. **(New)** The polynucleotide of claims 41-42 said polypeptide comprising the amino acid Cys at positions corresponding to amino acid positions 35, 49, 59 and 63 of SEQ ID NO:2.

45. **(New)** The polynucleotide of claim 44 with the amino acid Cys at positions corresponding to amino acid positions 83, 98, 114, 116, 119 and 126 of SEQ ID NO:2.

46. **(New)** The polynucleotide according to claim 45, said polynucleotide comprising the sequence SEQ ID NO:1.

47. **(New)** The polynucleotide according to claim 44, said polynucleotide comprising the sequence SEQ ID NO:1 or the sequence extending from nucleotides 55-385 of SEQ ID NO:1.

48. **(New)** A recombinant expression vector comprising the DNA according to claims 41-47.

49. **(New)** Polypeptide encoded by the polynucleotide according to claims 41-47 or the expression vector according to claim 48.

50. **(New)** A cell transfected with DNA according to claims 41-47 or the expression

vector according to claim 48.

51. **(New)** A cell according to claim 10 that is a transfected cell that expresses the protein according to claim 49.

52. **(New)** A method to produce the polypeptide of claim 49 the method comprising culturing the cells of claim 51 under conditions wherein said protein is produced and recovering said protein from the culture.

53. **(New)** A pharmaceutical composition comprising a polypeptide according to claim 49 in admixture with a pharmaceutically acceptable carrier.